#Italy #Milan #Pharmathen #NTC Pharma #Wise Equity

NTC Finalizes Acquisition of Pharmathen's Ophthalmology Business

NTC S.r.l., a prominent Italian pharmaceutical company focused on ophthalmology, has officially concluded the acquisition of Pharmathen's ophthalmology unit, a move bolstered by its principal investor, Wise Equity. This strategic acquisition is not merely a business transaction; it represents a major step towards enhancing NTC's position within the competitive European ophthalmology market.

With this acquisition, NTC aims to significantly strengthen its portfolio in the glaucoma treatment segment, positioning itself to achieve an impressive projected revenue of approximately 100 million euros, of which over 80% will derive from ophthalmic products. This transaction also sets the stage for NTC to broaden its international reach, particularly into the U.S. market, which is essential for growth in today's globalized economy.

Strategic Importance of the Acquisition

Riccardo Carbucicchio, CEO of NTC, commented on the relevance of this acquisition, stating, "Integrating Pharmathen's glaucoma therapies into our portfolio significantly enhances our commitment to delivering reliable and safe treatments for patients. With our established global network of partners, we are primed to extend this offering internationally."

The portfolio NTC gains from Pharmathen includes globally recognized, preservative-free formulations known for their effectiveness and safety in clinical practice. This aligns perfectly with NTC's mission to provide the highest therapeutic excellence, offering comprehensive solutions for complex ophthalmic issues.

John Nason, CEO of Pharmathen, emphasized the positive impact of the transition, reiterating, "By partnering with NTC, our ophthalmic products will be managed by a market leader in the field, ensuring continued investment and reliability in supply to our customer base while reaching a larger pool of patients."

Growth and Future Prospects

The acquisition of Pharmathen’s ophthalmology business is poised to enhance NTC's commercial operations significantly. Recent estimates suggest that glaucoma affects about 80 million people worldwide, a number forecasted to rise to nearly 112 million by 2040. The chronic nature of this disease underscores the importance of reliable treatment options, allowing NTC to play a crucial role in addressing a growing global health challenge.

In both Italy and Spain, where NTC has strategically positioned itself with a dedicated sales force geared towards ophthalmologists, this acquisition allows a holistic expansion of its therapeutic offerings in glaucoma treatments. Internationally, it facilitates substantial commercial synergies and opens new avenues for global expansion, especially in the lucrative U.S. market.

Having built a competitive pipeline of ophthalmologic products over the past decade, including therapies for antibiotic treatment, inflammation, allergies, and dry eye conditions, NTC is strategically evolving its portfolio to include advanced glaucoma treatments. This expansion not only solidifies NTC's position among the leading ophthalmic companies in Europe by unit sales but also extends its operational reach to over 100 countries, partnering with 250 distributors.

Investment Support and Future Vision

This acquisition has garnered strong support from Wise Equity, which specializes in investments in small and medium enterprises that exhibit a clear specialization and strong market position. As Stefano Ghetti, Senior Partner at Wise Equity, notes, "Our involvement in supporting NTC through this pivotal acquisition fits our investment philosophy of bolstering companies with significant identities and clear specializations."

Ascanio Recchi, an Investment Manager at Wise Equity, agrees, observing, "Entering the glaucoma market will substantially enhance NTC's business platform, significantly increasing its capacity to create long-term value in a sector experiencing heightened demand."

Given the critical need to address this pervasive health issue effectively, NTC is on its way to redefine its future, making substantial contributions to ophthalmic healthcare worldwide. With the strength of Wise Equity guiding its strategic initiatives, NTC stands ready to revolutionize the landscape of glaucoma treatments and expand its presence across the globe.

For further information about NTC and its commitment to innovating in ophthalmology, visit their official website at www.ntcpharma.com.
For details on Pharmathen's offerings, explore their resources at www.pharmathen.com.